首页> 外文OA文献 >Liquid biopsy and multi-analyte testing guided treatment of HER2 positive periampullary adenocarcinoma with durable complete response after trastuzumab based therapy

【2h】

Liquid biopsy and multi-analyte testing guided treatment of HER2 positive periampullary adenocarcinoma with durable complete response after trastuzumab based therapy

机译：液体活检和多分析物试验在基于曲妥珠单抗治疗后耐用的完全反应治疗HER2阳性胰腺炎腺癌的引导治疗

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Rajnish Nagarkar; Darshana Patil; Sewanti Limaye; Pradip Devhare; Ashwini Ghaisas; Navin Srivastava; Sachin Apurwa; Sanket Patil; Jinumary John; Zarrine Raazi; Aditya Shreenivas; Janani Sambath; Ajay Srinivasan; Prashant Kumar; Dadasaheb Akolkar; Rajan Datar;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. EORTC-1203-GITCG - the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group [J] . Anna Dorothea Wagner, Heike I. Grabsch, Murielle Mauer, BMC Cancer . 2019,第1期

机译：EORTC-1203-GITCG-“创新”试验：单纯化疗与化疗加曲妥珠单抗相比，与化疗加曲妥珠单抗加培妥珠单抗在围手术期治疗HER2阳性，胃和胃食管交界处腺癌对病理反应率的影响：随机阶段EORTC-胃肠道癌组，韩国癌症研究组和荷兰上消化道癌组的II组间试验
2. Durable complete response following chemotherapy and trastuzumab for metastatic her2-positive breast cancer [J] . GulloG., ZuradelliM., SclafaniF., Annals of oncology: official journal of the European Society for Medical Oncology . 2012,第8期

机译：化疗和曲妥珠单抗治疗转移性Her2阳性乳腺癌后的持久完全反应
3. Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancer [J] . G. Gullo1* M. Zuradelli2 F. Sclafani1 A. Santoro2 and J. Crown1 Annals of Oncology . 2012,第8期

机译：化疗和曲妥珠单抗对转移性HER2阳性乳腺癌的持久完全反应
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. Using Preoperative Mri-guided Biopsies to Predict Pathologic Complete Response after Neoadjuvant Chemotherapy in Breast Cancer [D] . Kim, Jiyoon. 2019

机译：在乳腺癌新辅助化疗后使用术前Mri引导的活检来预测病理完全缓解
6. EORTC-1203-GITCG - the INNOVATION-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab versus chemotherapy plus trastuzumab plus pertuzumab in the perioperative treatment of HER2 positive gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group Korean Cancer Study Group and Dutch Upper GI-Cancer group [O] . Anna Dorothea Wagner, Heike I. Grabsch, Murielle Mauer, 2019

机译：EORTC-1203-GITCG-创新试验：单纯化疗与化疗加曲妥珠单抗相比与化疗加曲妥珠单抗加帕妥珠单抗在围手术期治疗HER2阳性胃和胃食管交界处腺癌对病理反应率的影响：随机阶段EORTC-胃肠道癌组韩国癌症研究组和荷兰上消化道癌组的II组间试验
7. EORTC-1203-GITCG - the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group [O] . Anna Dorothea Wagner, Heike I. Grabsch, Murielle Mauer, 2019

机译：EORTC-1203-GITCG - “创新”-Trial：单独的化疗与化疗加上曲妥珠单抗，与化疗加曲妥珠单抗Plus Pertuzumab在病理反应率上的围手术期治疗中：随机阶段II-族胃肠道癌组，韩国癌症研究组和荷兰上GI-癌组的IN-CONTGROUP试验

Liquid biopsy and multi-analyte testing guided treatment of HER2 positive periampullary adenocarcinoma with durable complete response after trastuzumab based therapy

著录项

相似文献

相关主题

期刊订阅